Natco Pharma launches Bortezomib injection

Natco Pharma Ltd has announced the launch of its brand - Bortenat (Bortezomib) 3.5 mg. injection. Bortenat (Bortezomib) is used in the treatment of multiple myeloma.

Bortenat would be the first time launch of the Bortezomib generic in the World, in addition to being a first time introduction in India for the Company, this would be a most significant launch after Imatinib Mesylate (launched under the brand name VEENAT). The Company expects Bortenat to be a block buster and this launch would catapult the Company to #1 position among the domestic companies in the oncology segment.

Consistent with its policy of making life saving drugs affordable, the Company has priced Bortenat at Rs 16,800 MRP as against Rs 75,000 of the imported medicine. Being a pre 1995 invention, the Company does not expect any litigation around this molecule.

Multiple Myeloma (characterized by the abnormal plasma cell in the bone marrow) is cancer of the plasma cell, which represents the immune system that produces immunoglobulins to help fight infection and disease.

From among the several types of blood cancers, Multiple Myeloma is the second most prevalent and represents one percent of all cancers. From among cancer deaths, about 2% can be attributed to multiple myeloma. While the cause of multiple myeloma remains a mystery, in 99 per cent of the cases, multiple myeloma appears to have affected people over 40 years old.

Source : Equity Bulls

Keywords